Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [web-page on the Internet]Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report2017 Available from: http://goldcopd.org/gold-reports/Accessed November 28, 2017
   Google Scholar
• ThomasMDecramerMO’DonnellDENo room to breathe: the importance of lung hyperinflation in COPDPrim Care Respir J201322110111123429861
   PubMedGoogle Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD010844
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium (eMC) [webpage on the Internet]Seretide 100, 250, 500 Accuhaler. Summary of Product Characteristics (SmPC)2015 [updated 2015]. Available from: https://www.medicines.org.uk/emc/medicine/2317Accessed November 17, 2015
   Google Scholar
• Electronic Medicines Compendium (EMC) [webpage on the Internet]Eklira Genuair 322 Micrograms Inhalation Powder. Summary of Product Characteristics (SmPC)2015 [updated 21 May 2015]. Available from: https://www.medicines.org.uk/emc/medicine/27001Accessed June 15, 2015
   Google Scholar
• European Medicines Agency (EMA)Seebri Breezhaler. Summary of Product Characteristics (SmPC)2015 [updated October 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed October 14, 2015
   Google Scholar
• Electronic Medicines Compendium (EMC) [webpage on the Internet]Incruse 55 Micrograms inhalation Powder, Pre-dispensed. Summary of Product Characteristics (SmPC)2015 [updated September 2015]. Available from: https://www.medicines.org.uk/emc/medicine/29394Accessed October 8, 2015
   Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study-a randomised controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CatalunaJJCalleMSpanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phaseArch Bronconeumol201753632433528477954
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA)Committee for Medicinal Products for Human Use (CHMP) Assessment Report. Eklira Genuair (aclidinium bromide). Procedure No. EMEA/H/C/0022112012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002211/WC500132663.pdfAccessed June 15, 2015
   Google Scholar
• European Medicines Agency (EMA)Committee for Medicinal Products for Human Use (CHMP) Assessment Report. Incruse (umeclidinium bromide). Procedure No. EMEA/H/C/002809/00002014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002809/WC500167431.pdfAccessed June 15, 2015
   Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med2005143531732616144890
   PubMed Web of Science ®Google Scholar
• ChanCKMaltaisFSigouinCHaddonJMFordGTSAFE Study GroupA randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary diseaseCan Respir J200714846547218060091
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• TroostersTSciurbaFCDecramerMTiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialNPJ Prim Care Respir Med2014241400324841833
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• BatemanEDTashkinDSiafakasNA one-year trial of tiotropium Respimat plus usual therapy in COPD patientsRespir Med2010104101460147220620037
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res201112115622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med201414117825404569
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeslbaumARCaractaCFEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinERennardSHeTGilEGCaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• LaForceCPearleJFeldmanGEfficacy and safety of glycopyrronium in COPD patients with moderate-to-severe airflow limitation: the GEM1 studyAm J Respir Crit Care Med2015257Meeting AbstractsA5745
   Google Scholar
• KerwinESilerTMKorenblatPEGlycopyrronium twice daily improves lung function and health status and is well tolerated in COPD patients with moderate-to-severe airflow limitation: the GEM2 studyAm J Respir Crit Care Med2015257Meeting AbstractsA5742
   Google Scholar
• MenezesAMPerez-PadillaRWehrmeisterFCFEV1 is a better predictor of mortality than FVC: the PLATINO cohort studyPLoS One2014910e10973225285441
   PubMed Web of Science ®Google Scholar
• KeXMarvelJYuTCImpact of lung function on exacerbations, health care utilization, and costs among patients with COPDInt J Chron Obstruct Pulmon Dis2016111689170327555759
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Spirometry for Healthcare Providers2010 Available from: http://goldcopd.org/wp-content/uploads/2016/04/GOLD_Spirometry_2010.pdfAccessed December 11, 2017
   Google Scholar
• CelliBZuwallackRWangSKestenSImprovement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumesChest200312451743174814605043
   PubMed Web of Science ®Google Scholar
• KostikasKSiafakasNMDoes the term “deflators” reflect more accurately the beneficial effects of long-acting bronchodilators in COPD?COPD201613553753927115572
   PubMedGoogle Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med2011105458058721183326
   PubMed Web of Science ®Google Scholar
• JonesPHigenbottamTQuantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantificationProc Am Thorac Soc20074859760118073389
   PubMedGoogle Scholar
• ChapmanKVogelmeierCFowlerTaylorAEffect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: results from the FLAME studyEur Respir J201648suppl 60A296
   Google Scholar
• European Respiratory Society (ERS) [webpage on the Internet]Chapter 13: chronic obstructive pulmonary diseaseEuropean Lung White Book2016 [updated 2016]. Available from: http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/Accessed November 24, 2016
   Google Scholar
• JonesPWSinghDKerwinELamarcaRCaractaCGarcia GilEReduced COPD exacerbations associated with aclidinium bromide versus placebo: a pooled analysis of Phase III dataThorax201267suppl 2A146 (Abstract P189).
   Web of Science ®Google Scholar
• MahlerDAWellsCKEvaluation of clinical methods for rating dyspneaChest19889335805863342669
   PubMed Web of Science ®Google Scholar
• MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
   PubMed Web of Science ®Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory QuestionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• JonesPWSt. George’s respiratory questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med2014141424438744
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDRocheNAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar
• IsmailaASHuismanELPunekarYSKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2015102495251726604738
   PubMed Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840542324043936
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHOnce-daily glycopyrronium via Breezhaler^® device improves lung function and reduces exacerbations in severe-to-very severe COPD patients: the SPARK study7th International Primary Care Respiratory Group World ConferenceAthens, Greece2014 Abstract OR-081
   Google Scholar
• WedzichaJAAgustiADonaldsonGChuecosFLamarcaRGarcia GilEEffect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five phase III, randomized, placebo-controlled studiesCOPD201613666967627159613
   PubMedGoogle Scholar
• JonesPWBrusselleGDal NegroRWHealth-related quality of life in patients by COPD severity within primary care in EuropeRespir Med20111051576620932736
   PubMed Web of Science ®Google Scholar
• JonesRCPriceDRyanDOpportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohortLancet Respir Med20142426727624717623
   PubMed Web of Science ®Google Scholar
• KardosPVogelmeierCBuhlRCrieeCPWorthHThe Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methodsBMC Pulm Med201515225578330
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCrieeCPKardosPMailanderCVogelmeierCThe ‘real-life’ COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
   PubMed Web of Science ®Google Scholar
• MiravitllesMPriceDRabeKFSchmidtHMetzdorfNCelliBComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151054956425834416
   PubMed Web of Science ®Google Scholar
• VanfleterenLESpruitMAGroenenMClusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187772873523392440
   PubMed Web of Science ®Google Scholar
• TraversJMarshSCaldwellBExternal validity of randomized controlled trials in COPDRespir Med200710161313132017113277
   PubMed Web of Science ®Google Scholar
• RedelmeierDATanSHBoothGLThe treatment of unrelated disorders in patients with chronic medical diseasesN Engl J Med199833821151615209593791
   PubMed Web of Science ®Google Scholar
• PolkeyMIRabeKFChicken or egg: physical activity in COPD revisitedEur Respir J200933222722919181910
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• PittaFTroostersTProbstVSSpruitMADecramerMGosselinkRPhysical activity and hospitalization for exacerbation of COPDChest2006129353654416537849
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• ConnorsAFJrDawsonNVThomasCOutcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)Am J Respir Crit Care Med19961544 pt 19599678887592
   PubMed Web of Science ®Google Scholar
• RabeKFFabbriLMIsraelEEffect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trialLancet Respir Med201421445324461901
   PubMed Web of Science ®Google Scholar
• D’UrzoADonohueJFKardosPMiravitllesMPriceDA reevaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseExpert Opin Pharmacother201516121845186026194213
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCurr Med Res Opin201430349350824156566
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• MahlerDAKeiningerDLMezziKFogelRBanerjiDEfficacy of indacaterol/glycopyrronium in patients with COPD who have increased dyspnea with daily activitiesChronic Obstr Pulm Dis20163475876828848901
   PubMedGoogle Scholar
• BatemanEDMahlerDAVogelmeierCFWedzichaJAPatalanoFBanerjiDRecent advances in COPD disease management with fixed-dose long-acting combination therapiesExpert Rev Respir Med20148335737924802656
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• PascoeSJLipsonDALocantoreNA phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocolEur Respir J201648232033027418551
   PubMed Web of Science ®Google Scholar
• MagnussenHTetzlaffKBatemanEDLung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPDEur Respir J201647265165426585433
   PubMed Web of Science ®Google Scholar
• CalverleyPMCOPD therapy: if two is good, is three better?Lancet20163881004893793827598662
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPDRespir Med2013107456056923352226
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• SiafakasNCorlateanuAFoukaEPhenotyping before starting treatment in COPD?COPD201714336737428388265
   PubMedGoogle Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance COPD treatment: data from the FLAME trialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• MiravitllesMAnzuetoAA new two-step algorithm for the treatment of COPDEur Respir J2017492
   Web of Science ®Google Scholar
• MiravitllesMD’UrzoASinghDKoblizekVPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewRespir Res201617111227613392
   PubMed Web of Science ®Google Scholar
• ColthorpePVoshaarTKiekbuschTCuoghiEJauernigJDelivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrroniumJ Drug Assess201321111627536432
   PubMedGoogle Scholar
• Lyseng-WilliamsonKAKeatingGMTiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EUDrugs Ther Perspect2015313944
   Google Scholar
• GjaltemaDHagedoornPGrasmeijerFHuijbersBGFrijlinkHWde BoerAHComparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhalerEur Respir J201342suppl 57692s (Abstract P3384).
   Google Scholar
• SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• GrantACWalkerRHamiltonMGarrillKThe ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregiversJ Aerosol Med Pulm Drug Deliv201528647448526372466
   PubMed Web of Science ®Google Scholar
• ChrystynHNiederlaenderCThe Genuair® inhaler: a novel, multidose dry powder inhalerInt J Clin Pract201266330931722340451
   PubMed Web of Science ®Google Scholar
• MolimardMRaherisonCLignot-MaleyranSChronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patientsEur Respir J201749160179428182569
   PubMed Web of Science ®Google Scholar
• IngebrigtsenTSMarottJLNordestgaardBGLow use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general populationJ Gen Intern Med2015301515925245885
   PubMed Web of Science ®Google Scholar
• MehuysEBousseryKAdriaensECOPD management in primary care: an observational, community pharmacy-based studyAnn Pharmacother201044225726620103611
   PubMed Web of Science ®Google Scholar
• MäkeläMJBackerVHedegaardMLarssonKAdherence to inhaled therapies, health outcomes and costs in patients with asthma and COPDRespir Med2013107101481149023643487
   PubMed Web of Science ®Google Scholar
• BerezaBGTroelsgaard NielsenAValgardssonSHemelsMEEinarsonTRPatient preferences in severe COPD and asthma: a comprehensive literature reviewInt J Chron Obstruct Pulmon Dis20151073974425914530
   PubMed Web of Science ®Google Scholar
• MolimardMColthorpePInhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitionersJ Aerosol Med Pulm Drug Deliv201528321922825265316
   PubMed Web of Science ®Google Scholar
• PriceDLeeAJSimsEJCharacteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort studyPrim Care Respir J201322216116823460035
   PubMedGoogle Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• DederichsJSinghDPavkovRInspiratory flow profiles generated by patients with COPD through the Breezhaler® inhaler and other marketed dry powder inhalersAm J Respir Crit Care Med2015191A5793
   Web of Science ®Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• KomaseYAsakoAKobayashiASharmaREase-of-use preference for the ELLIPTA(R) dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or olderInt J Chron Obstruct Pulmon Dis201491365137525525354
   PubMed Web of Science ®Google Scholar
• PascualSFeimerJDe SoyzaAPreference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre studyNPJ Prim Care Respir Med2015251501825927321
   PubMed Web of Science ®Google Scholar
• van der PalenJGinkoTKrokerAPreference, satisfaction and errors with two dry powder inhalers in patients with COPDExpert Opin Drug Deliv20131081023103123745954
   PubMed Web of Science ®Google Scholar
• HananiaNACelliBRDonohueJFMartinUJBronchodilator reversibility in COPDChest201114041055106321972384
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA) [webpage on the Internet]2017 Pocket Guide for Asthma Management and Prevention2017 Available from: http://ginasthma.org/2017-pocket-guide-for-asthma-management-and-preventionAccessed December 11, 2017
   Google Scholar